Intracerebral hemorrhage (ICH) is the only form of stroke without a clearly defined treatment. It occurs in more than 100,000 Americans each year, with 30% to 50% mortality and significant motor and cognitive disabilities in the majority of survivors. Minorities bear an increased burden of disease. The severity of the injury is directly related to blood clot volume and time blood is exposed to brain. No trial has been organized to test the hypothesis that blood clot removal benefits the ICH stroke patient. The MISTIE trial is a proof of concept clinical trial with sufficient statistical power to provide a definitive evaluation of the safety and clinical benefit of image-based, minimally invasive surgery (MIS) to aspirate clot in combination with instillations of rt-PA following surgery for further clot dissolution. The trial is in two steps: Dose Optimization followed by a Safety Study. The study will be completed over 7 years, using an intent-to-treat analysis. The original goal and hypotheses are unchanged. The current results have already provided first-time data about rt-PA safety and clot dissolution, patient selection, patient stability, quantitation of MIS surgical effectiveness and definition of treatment related complications. The test surgery, MIS + rt-PA, was performed in 24 subjects with minimal mortality and acceptable morbidity compared to 6 control subjects. Seven of the original eight centers are performing the surgical procedure and the trial procedures effectively and enthusiastically. The surgical procedure has been graded as acceptable by the independent surgical center in 96% of the procedures performed. This surgery has led to substantial reduction of clot size in the majority of subjects. We have removed 50% or more of the clot in 83% of subjects (average volume removed 27 cc) and met the predetermined surgical removal goals in 62.5% of randomized subjects. The final safety and outcome results are pending completion of recruitment. These results will provide robust estimates of effect of MIS on outcome for ICH. The long-term goal of this research is to change the way ICH is treated, that is, to reduce brain injury with innovative and forward-looking minimally invasive surgical management. This type II funding proposal requests $2.9 million to sustain trial infrastructure to complete recruitment and test the original hypothesis.

Public Health Relevance

Intracerebral hemorrhage (ICH) is the only form of stroke without an effective treatment. Intracerebral hemorrhage occurs in over 100,000 Americans each year. It is fatal in 30% to 50% of all occurrences and leaves the majority of the survivors with significant motor and cognitive disability. Minorities bear an increased burden of disease in ICH. Compared to ischemic stroke, ICH is easily and rapidly identified: it occurs in younger patients and initially produces a smaller injury to the cerebral tissues, suggesting that interventional amelioration is possible with the right treatment, such as image- guided, minimally invasive surgery. Yet, of the major stroke subtypes-ischemic, aneurysm rupture, and intracerebral hemorrhage-intracerebral hemorrhage is the only major subtype without a clearly defined treatment.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Janis, Scott
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
Schools of Medicine
United States
Zip Code
Hansen, Björn M; Morgan, Timothy C; Betz, Joshua F et al. (2016) Intraventricular Extension of Supratentorial Intracerebral Hemorrhage: The Modified Graeb Scale Improves Outcome Prediction in Lund Stroke Register. Neuroepidemiology 46:43-50
Hanley, Daniel F; Thompson, Richard E; Muschelli, John et al. (2016) Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurol 15:1228-1237
Colantuoni, Elizabeth; Rosenblum, Michael (2015) Leveraging prognostic baseline variables to gain precision in randomized trials. Stat Med 34:2602-17
Webb, Alastair J S; Ullman, Natalie L; Morgan, Tim C et al. (2015) Accuracy of the ABC/2 Score for Intracerebral Hemorrhage: Systematic Review and Analysis of MISTIE, CLEAR-IVH, and CLEAR III. Stroke 46:2470-6
Kornbluth, J; Nekoovaght-Tak, S; Ullman, N et al. (2015) Early Quantification of Hematoma Hounsfield Units on Noncontrast CT in Acute Intraventricular Hemorrhage Predicts Ventricular Clearance after Intraventricular Thrombolysis. AJNR Am J Neuroradiol 36:1609-15
Muschelli, John; Ullman, Natalie L; Sweeney, Elizabeth M et al. (2015) Quantitative Intracerebral Hemorrhage Localization. Stroke 46:3270-3
Muschelli, John; Ullman, Natalie L; Mould, W Andrew et al. (2015) Validated automatic brain extraction of head CT images. Neuroimage 114:379-85
Ziai, Wendy C; Tuhrim, Stanley; Lane, Karen et al. (2014) A multicenter, randomized, double-blinded, placebo-controlled phase III study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). Int J Stroke 9:536-42
Dye, Justin A; Rees, Galya; Yang, Isaac et al. (2014) Neuropathologic analysis of hematomas evacuated from patients with spontaneous intracerebral hemorrhage. Neuropathology 34:253-60
Barnes, Benjamin; Hanley, Daniel F; Carhuapoma, Juan R (2014) Minimally invasive surgery for intracerebral haemorrhage. Curr Opin Crit Care 20:148-52

Showing the most recent 10 out of 27 publications